Association of angiogenesis and inflammation‑related gene functional polymorphisms with early‑stage breast cancer prognosis

Korobeinikova,Erika; Ugenskiene,Rasa; Insodaite,Ruta; Rudzianskas,Viktoras; Jaselske,Evelina; Poskiene,Lina; Juozaityte,Elona

doi:10.3892/ol.2020.11521

Association of angiogenesis and inflammation‑related gene functional polymorphisms with early‑stage breast cancer prognosis

Authors:
- Erika Korobeinikova
- Rasa Ugenskiene
- Ruta Insodaite
- Viktoras Rudzianskas
- Evelina Jaselske
- Lina Poskiene
- Elona Juozaityte
View Affiliations

Affiliations: Oncology Institute, Lithuanian University of Health Sciences, LT‑50009 Kaunas, Lithuania, Oncology Research Laboratory, Oncology Institute, Lithuanian University of Health Sciences, LT‑50009 Kaunas, Lithuania, Biology System and Genetic Research Institute, Lithuanian University of Health Sciences, LT‑50161 Kaunas, Lithuania, Department of Pathological Anatomy, Medical Academy, Lithuanian University of Health Sciences, LT‑50009 Kaunas, Lithuania
Published online on: April 7, 2020 https://doi.org/10.3892/ol.2020.11521
Pages: 3687-3700
Copyright: © Korobeinikova et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Genetic variations in inflammation- and angiogenesis-related genes may alter the coded protein level and impact the pathogenesis of breast cancer (BC). The present study investigated the association of functional single nucleotide polymorphisms (SNPs) in the VEGFA, IL‑1β, IL‑1α and IL‑6 genes with the early‑stage BC phenotype and survival. Genomic DNA and clinical data were collected for 202 adult Eastern European (Lithuanian) women with primary I‑II stage BC. Genotyping of the SNPs was performed using TaqMan SNP genotyping assays. Nine VEGFA, IL‑1β, IL‑1α and IL‑6 polymorphisms were analysed. The VEGFA and IL‑6 haplotypes were inferred using Phase software. Patients were prospectively followed‑up for recurrence, occurrence of metastasis and mortality until April 30, 2019. All studied genotypes were in Hardy‑Weinberg equilibrium and had the same distribution as the 1,000 Genomes project Phase 3 dataset for European population. Significant associations of the studied SNPs with clinicopathologic variables were observed between IL‑1α rs1800587 C allele and larger primary tumour size; IL‑6 rs1800797 A allele, rs1800797 GA genotype, rs1800795 C allele, IL‑6 (rs1800797‑re1800795) AC diplotype and hormonal receptor‑positive disease; IL‑6 rs1800797 A allele and HER2 negative status. In univariate Cox survival analysis, IL‑1α rs1800587 CC and IL‑6 rs1800797 GG genotype carriers exhibited worse disease‑free survival (DFS), metastasis‑free survival (MFS) and overall survival (OS). The IL‑6 rs1800795 GG genotype was associated with worse OS. IL‑6 (rs1800797, rs1800795) GG/GG diplotype carriers had shorter MFS and OS. Multivariate Cox survival analysis revealed that the IL‑1α rs1800587 CC genotype was an independent negative prognostic factor for DFS, MFS and OS, and the IL6 GG/GG diplotype was an independent negative prognostic factor for MFS and OS. According to the present study, functional SNPs in the IL‑1α and IL‑6 genes may contribute to the identification of patients at higher risk of BC recurrence, development of metastases and worse OS among early‑stage patients with BC.

View Figures

View References

1	IARC: World Cancer Report 2014. Stewart BW and Wild CP: IARC; Lyon: 2014
2	Cancer Trends Progress Report. National Cancer Institute, NIH, DHHS; Bethesda, MD: 2019, https://progressreport.cancer.gov
3	Zhao Y and Adjei AA: Targeting angiogenesis in cancer therapy: Moving beyond vascular endothelial growth factor. Oncologist. 20:660–673. 2015. View Article : Google Scholar : PubMed/NCBI
4	Bielenberg DR and Zetter BR: The contribution of angiogenesis to the process of metastasis. Cancer J. 21:267–273. 2015. View Article : Google Scholar : PubMed/NCBI
5	Cartland SP, Genner SW, Zahoor A and Kayurma MM: Comparative evaluation of TRAIL, FGF-2 and VEGF-A-induced angiogenesis in vitro and in vivo. Int J Mol Sci. 17:E20252016. View Article : Google Scholar : PubMed/NCBI
6	De Palma M, Biziato D and Petrova TV: Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 17:457–474. 2017. View Article : Google Scholar : PubMed/NCBI
7	Marech I, Leporini C, Ammendola M, Porcelli M, Gadaleta CD, Russo E, De Sarro G and Ranieri G: Classical and non-classical proangiogenic factors as a target of antiangiogenic yherapy in tumor microenvironment. Cancer Lett. 380:216–226. 2016. View Article : Google Scholar : PubMed/NCBI
8	Banys-Paluchoothtwski M, Witzel I, Riethdorf S, Pantel K, Rack B, Janni W, Fasching PA, Aktas B, Kasimir-Bauer S, Hartkopf A, et al: The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer. Breast Cancer Res Treat. 172:93–104. 2018. View Article : Google Scholar : PubMed/NCBI
9	Gyamfi J, Eom M, Koo JS and Choi J: Multifaceted roles of interleukin-6 in adipocyte-breast cancer cell interaction. Transl Oncol. 11:275–285. 2018. View Article : Google Scholar : PubMed/NCBI
10	Knüpfer H and Preiss R: Significance of interleukin-6 (IL-6) in breast cancer (Review). Breast Cancer Res Treat. 102:129–135. 2007. View Article : Google Scholar : PubMed/NCBI
11	Tawara K, Scott H, Emathinger J, Ide A, Fox R, Greiner D, LaJoie D, Hedeen D, Nandakumar M, Oler AJ, et al: Co-expression of VEGF and IL-6 family cytokines is associated with decreased survival in HER2 negative breast cancer patients: Subtype-specific IL-6 family cytokine-mediated VEGF secretion. Transl Oncol. 12:245–255. 2019. View Article : Google Scholar : PubMed/NCBI
12	Litmanovich A, Khazim K and Cohen I: The role of interleukin-1 in the pathogenesis of cancer and its potential as a therapeutic target in clinical practice. Oncol Ther. 6:109–127. 2018. View Article : Google Scholar
13	Balasubramanian SP, Azmy IA, Higham SE, Wilson AG, Cross SS, Cox A, Brown NJ and Reed MW: Interleukin gene polymorphisms and breast cancer: A case control study and systematic literature review. BMC Cancer. 6:1882006. View Article : Google Scholar : PubMed/NCBI
14	Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E and Siviridis E: VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer. 46:293–298. 2004. View Article : Google Scholar : PubMed/NCBI
15	Watson CJ, Webb NJ, Bottomley MJ and Brenchley PE: Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: Correlation with variation in VEGF protein production. Cytokine. 12:1232–1235. 2000. View Article : Google Scholar : PubMed/NCBI
16	Ray D, Mishra M, Ralph S, Read I, Davies R and Brenchley P: Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes. 53:861–864. 2004. View Article : Google Scholar : PubMed/NCBI
17	Hall SK, Perregaux DG, Gabel CA, Woodworth T, Durham LK, Huizinga TW, Breedveld FC and Seymour AB: Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein. Arthritis Rheum. 50:1976–1983. 2004. View Article : Google Scholar : PubMed/NCBI
18	Um JY, Rim HK, Kim SJ, Kim HL and Hong SH: Functional polymorphism of IL-1 alpha and its potential role in obesity in humans and mice. PLoS One. 6:e295242011. View Article : Google Scholar : PubMed/NCBI
19	Rana BK, Flatt SW, Health DD, Pakiz B, Quintana EL, Natarajan L and Rock CL: The IL-6 gene promoter SNP and plasma IL-6 in response to diet intervention. Nutrients. 9:E5522017. View Article : Google Scholar : PubMed/NCBI
20	Boeta-Lopez K, Duran J, Elizondo D, Gonzales E, Rentfro A, Schwarzbach AE and Nair S: Association of interleukin-6 polymorphisms with obesity or metabolic traits in young Mexican-Americans. Obes Sci Pract. 4:85–96. 2017. View Article : Google Scholar : PubMed/NCBI
21	Sampaio AM, Balseiro SC, Silva MR, Alarcão A, d'Aguiar MJ, Ferreira T and Carvalho L: Association between IL-4 and IL-6 expression variants and gastric cancer among portuguese population. GE Port J Gastroenterol. 22:143–152. 2015. View Article : Google Scholar : PubMed/NCBI
22	Langsenlehner U, Hofmann G, Renner W, Gerger A, Krenn-Pilko S, Thurner EM, Krippl P and Langsenlehner T: Association of vascular endothelial growth factor--a gene polymorphisms and haplotypes with breast cancer metastases. Acta Oncol. 54:368–376. 2015. View Article : Google Scholar : PubMed/NCBI
23	Escala-Garcia M, Guo Q, Dörk T, Canisius S, Keeman R, Dennis J, Beesley J, Lecarpentier J, Bolla MK, Wang Q, et al: Genome-wide association study of germline variants and breast cancer-specific mortality. Br J Cancer. 120:647–657. 2019. View Article : Google Scholar : PubMed/NCBI
24	Khan S, Fagerholm R, Kadalayil L, Tapper W, Aittomäki K, Liu J, Blomqvist C, Eccles D and Nevanlinna H: Meta-analysis of three genome-wide association studies identifies two loci that predict survival and treatment outcome in breast cancer. Oncotarget. 9:4249–4257. 2017.PubMed/NCBI
25	Peng X, Shi J, Sun W, Ruan X, Guo Y, Zhao L, Wang J and Li B: Genetic polymorphisms of IL-6 promoter in cancer susceptibility and prognosis: A meta-analysis. Oncotarget. 9:12351–12364. 2018. View Article : Google Scholar : PubMed/NCBI
26	Abana CO, Bingham BS, Cho JH, Graves AJ, Koyama T, Pilarski RT, Chakravarthy AB and Xia F: IL-6 variant is associated with metastasis in breast cancer patients. PLoS One. 12:e01817252017. View Article : Google Scholar : PubMed/NCBI
27	DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M, Athanasiadis G, Colligan T, Stadtmauer E and Weber B: Interleukin-6 −174G->C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res. 63:8051–8056. 2003.PubMed/NCBI
28	DeMichele A, Gray R, Horn M, Chen J, Aplenc R, Vaughan WP and Tallman MS: Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer. Cancer Res. 69:4184–4191. 2009. View Article : Google Scholar : PubMed/NCBI
29	Markkula A, Simonsson M, Ingvar C, Rose C and Jernström H: IL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohort. BMC Cancer. 14:7592014. View Article : Google Scholar : PubMed/NCBI
30	Xia H, Chen Y, Meng J and Liang C: Effect of polymorphisms on IL1A to cancer susceptibility: Evidence based on 34,016 subjects. Artif Cells Nanomed Biotechnol. 47:3138–3152. 2019. View Article : Google Scholar : PubMed/NCBI
31	Grimm C, Kantelhardt E, Heinze G, Polterauer S, Zeillinger R, Kölbl H, Reinthaller A and Hefler L: The prognostic value of four interleukin-1 gene polymorphisms in Caucasian women with breast cancer: A multicenter study. BMC Cancer. 9:782009. View Article : Google Scholar : PubMed/NCBI
32	Snoussi K, Strosberg AD, Bouaouina N, Ben Ahmed S and Chouchane L: Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma. Eur Cytokine Netw. 16:253–260. 2005.PubMed/NCBI
33	Hayes DF, Ethier S and Mippman ME: New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat. 100:237–238. 2006. View Article : Google Scholar : PubMed/NCBI
34	McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M and Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics, : Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 97:1180–1184. 2005. View Article : Google Scholar : PubMed/NCBI
35	1000 Genomes Project Consortium, ; Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA and Abecasis GR: A global reference for human genetic variation. Nature. 526:68–74. 2015. View Article : Google Scholar : PubMed/NCBI
36	Barrett JC, Fry B, Maller J and Daly MJ: Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics. 21:263–265. 2005. View Article : Google Scholar : PubMed/NCBI
37	Stephens M, Smith NJ and Donnelly P: A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 68:978–989. 2001. View Article : Google Scholar : PubMed/NCBI
38	Stephens M and Scheet P: Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet. 76:449–462. 2005. View Article : Google Scholar : PubMed/NCBI
39	Kumari N, Dwarakanath BS, Das A and Bhatt AN: Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 37:11553–11572. 2016. View Article : Google Scholar : PubMed/NCBI
40	Dethlefsen C, Højfeldt G and Hojman P: The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat. 138:657–664. 2013. View Article : Google Scholar : PubMed/NCBI
41	Masjedi A, Hashemi V, Hojjat-Farsangi M, Ghalamfarsa G, Azizi G, Yousefi M and Jadidi-Niaragh F: The significant role of IL-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. Biomed Pharmacother. 108:1415–1424. 2018. View Article : Google Scholar : PubMed/NCBI